Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Change in Receivables (2021 - 2024)

Historic Change in Receivables for IDEAYA Biosciences (IDYA) over the last 4 years, with Q4 2024 value amounting to -$2000.0.

  • IDEAYA Biosciences' Change in Receivables rose 9997.01% to -$2000.0 in Q4 2024 from the same period last year, while for Sep 2024 it was -$6.7 million, marking a year-over-year decrease of 30537.8%. This contributed to the annual value of -$193000.0 for FY2023, which is 7836.32% up from last year.
  • Per IDEAYA Biosciences' latest filing, its Change in Receivables stood at -$2000.0 for Q4 2024, which was up 9997.01% from $19000.0 recorded in Q3 2024.
  • Over the past 5 years, IDEAYA Biosciences' Change in Receivables peaked at $6.5 million during Q3 2023, and registered a low of -$6.7 million during Q4 2023.
  • In the last 4 years, IDEAYA Biosciences' Change in Receivables had a median value of -$8500.0 in 2024 and averaged -$116187.5.
  • Within the past 5 years, the most significant YoY rise in IDEAYA Biosciences' Change in Receivables was 112964.17% (2022), while the steepest drop was 390941.18% (2022).
  • IDEAYA Biosciences' Change in Receivables (Quarter) stood at $85000.0 in 2021, then crashed by 3909.41% to -$3.2 million in 2022, then tumbled by 106.45% to -$6.7 million in 2023, then skyrocketed by 99.97% to -$2000.0 in 2024.
  • Its Change in Receivables stands at -$2000.0 for Q4 2024, versus $19000.0 for Q3 2024 and -$14000.0 for Q2 2024.